News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,879 Results
Type
Article (14266)
Company Profile (105)
Press Release (259500)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88272)
Career Advice (465)
Deals (15392)
Drug Delivery (73)
Drug Development (36715)
Employer Resources (50)
FDA (6384)
Job Trends (6232)
News (150703)
Policy (14130)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (13)
Adcomms (8)
Allergies (69)
Alliances (23317)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6574)
Artificial intelligence (202)
Autoimmune disease (42)
Automation (12)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (172)
Cancer (1319)
Cardiovascular disease (152)
Career advice (418)
Career pathing (13)
CAR-T (50)
CDC (6)
Cell therapy (152)
Cervical cancer (9)
Clinical research (32023)
Collaboration (735)
Compensation (326)
Complete response letters (33)
COVID-19 (779)
CRISPR (43)
C-suite (438)
Cystic fibrosis (58)
Data (1829)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1384)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (117)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (33474)
Editorial (20)
Employer branding (4)
Employer resources (46)
Events (38988)
Executive appointments (531)
FDA (7486)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (433)
Gene editing (70)
Generative AI (18)
Gene therapy (166)
GLP-1 (442)
Government (1406)
Grass and pollen (4)
Guidances (164)
Healthcare (3575)
HIV (12)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (69)
Immuno-oncology (15)
Indications (53)
Infectious disease (843)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3449)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (417)
MASH (67)
Medical device (1302)
Medtech (1309)
Mergers & acquisitions (9902)
Metabolic disorders (438)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (83)
Neuropsychiatric disorders (37)
Neuroscience (890)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (231)
Opinion (141)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29752)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8305)
Phase 2 (13521)
Phase 3 (12212)
Pipeline (1931)
Policy (135)
Postmarket research (1401)
Preclinical (3340)
Press Release (25)
Prostate cancer (85)
Psychedelics (16)
Radiopharmaceuticals (136)
Rare diseases (352)
Real estate (2659)
Recruiting (19)
Regulatory (10963)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (53)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1645)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (234)
Venture capital (32)
Weight loss (142)
Women's health (28)
Worklife (4)
Date
Today (54)
Last 7 days (188)
Last 30 days (732)
Last 365 days (10441)
2026 (1028)
2025 (10712)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19032)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20897)
Australia (2687)
California (3187)
Canada (1490)
China (554)
Colorado (144)
Connecticut (129)
Delaware (124)
Europe (40881)
Florida (603)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (349)
India (45)
Indiana (241)
Iowa (2)
Japan (248)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (422)
Massachusetts (2603)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1401)
New Mexico (7)
New York (907)
North Carolina (624)
North Dakota (2)
Northern California (1453)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (720)
Puerto Rico (13)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1392)
Tennessee (53)
Texas (455)
United States (12721)
Utah (60)
Virginia (161)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (38)
Wyoming (1)
273,879 Results for "satsuma pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
November 6, 2025
·
7 min read
Press Releases
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society’s 67th Annual Scientific Meeting
June 19, 2025
·
5 min read
Press Releases
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
May 1, 2025
·
9 min read
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 66th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.
June 13, 2024
·
6 min read
Press Releases
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
November 26, 2024
·
5 min read
Deals
SNBL to Acquire Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.
April 16, 2023
·
10 min read
Press Releases
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
October 31, 2024
·
5 min read
Drug Development
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
October 8, 2024
·
8 min read
Biotech Bay
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
Satsuma Pharmaceuticals, Inc . today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting.
April 21, 2023
·
4 min read
Biotech Bay
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) today announced that John Kollins, President and Chief Executive Officer, will deliver a company presentation during the SVB Securities Global Biopharma Conference, which is being held virtually February 14-16.
February 2, 2023
·
2 min read
1 of 27,388
Next
